DelveInsight’s, “Knee Osteoarthritis Pipeline Insight” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Knee Osteoarthritis pipeline landscape. It covers the Knee Osteoarthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Knee Osteoarthritis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Knee Osteoarthritis pipeline products in this space.

 

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Knee Osteoarthritis Pipeline Report to explore emerging therapies, key Knee Osteoarthritis Companies, and future Knee Osteoarthritis treatment landscapes @ Knee Osteoarthritis Pipeline Outlook Report

 

Key Takeaways from the Knee Osteoarthritis Pipeline Report

• In February 2025:- Medipost Co. Ltd:- This clinical trial is for patients who have been diagnosed with Kellgren-Lawrence (K&L) Grade 2 or 3 knee osteoarthritis on radiographic examination. Only subjects who voluntarily agree to participate by filling out the written Informed Consent document will undergo screening for subject selection (inclusion/exclusion) criteria, at which time the severity of OA in each knee will be used to determined which knee will be treated (index knee – i.e., the more severely affected knee), and enroll in this study.
• In January 2025:- Novartis Pharmaceuticals:- The purpose of this study is to evaluate the articular cartilage-regenerating capacity of RHH646 in the knee as well as to assess safety and tolerability in participants with knee osteoarthritis. The treatment duration will be up to 52 weeks. The total study duration for an individual participant will be up to 62 weeks.
• In January 2025:- ArthroBiologix Inc.:- The purpose of this study is to determine whether outcomes for patients receiving intra-articular platelet-rich plasma (PRP) injections for knee osteoarthritis are influenced by observation of the preparatory steps to the procedure. The viewing of the steps involved in the administration of PRP may increase the effectiveness of the treatment in comparison to patients who have not observed the preparatory steps.
• DelveInsight’s Knee Osteoarthritis pipeline report depicts a robust space with 50+ active players working to develop 60+ pipeline therapies for Knee Osteoarthritis treatment.
• The leading Knee Osteoarthritis Companies such as Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Centrexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, AbbVie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Eupraxia Pharmaceuticals, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, PT. Prodia Stem Cell Indonesia and others.
• Promising Knee Osteoarthritis Therapies such as Civamide, Clodronate, LBSA0103, Glucosamine and chondroitin sulfate combination (Eurofarma), RN624 (PF-04383119) and others.

 

Discover how the Knee Osteoarthritis treatment paradigm is evolving. Access DelveInsight’s in-depth Knee Osteoarthritis Pipeline Analysis for a closer look at promising breakthroughs @ Knee Osteoarthritis Clinical Trials and Studies

 

Knee Osteoarthritis Emerging Drugs Profile

 

• Lorecivivint: Biosplice Therapeutics

Lorecivivint (SM04690) is a small-molecule CLK/DYRK1A inhibitor that modulates Wnt and inflammatory pathways and is in development as a potential disease-modifying osteoarthritis drug. Vehicle-controlled preclinical data suggest that lorecivivint has a dual mechanism of action with three potential effects on joint health: reduction of inflammation, slowing of cartilage breakdown, and generation of cartilage. Currently, the drug is in Phase III stage of its development for the treatment of Knee Osteoarthritis.

 

• EP-104IAR: Eupraxia Pharmaceuticals Inc.

EP-104IAR, is designed to meet the significant unmet medical need and market demand for long-lasting disease relief in multiple indications benefitting from highly localized and longer delivery of corticosteroids. The lead indication is for pain relief in knee OA. With EP-104IAR, Eupraxia hopes to change the way knee OA pain is treated. Currently approved corticosteroids are very effective at reducing pain for a short duration late in the disease but can expose the body to unwanted local and systemic side effects. EP-104IAR is designed to prolong the duration of pain relief with fewer unwanted side effects. It encapsulates a highly potent corticosteroid (fluticasone propionate) within a microns-thin polymer membrane, part of Eupraxia’s patented technology platform. Injected into the knee, EP-104IAR is designed to diffuse the corticosteroid slowly into the knee joint providing local therapeutic concentrations for up to six months. This has the potential dual advantage of providing longer duration of pain relief with fewer systemic side effects. A robust safety and tolerability profile would also benefit the estimated 70% of knee OA patients that experience pain in both knees by allowing simultaneous treatment of both affected joints. Currently, the drug is in Phase II stage of its development for the treatment of Knee Osteoarthritis.

 

• LG00034053: LG Chem

LG34053 is an injectable new drug with a new mechanism of blocking the inflammatory pathway and inhibiting chondrocyte apoptosis. LG Chem expects that the new drug will be different from existing symptomatic pain relief drugs. LG00034053 is the world’s first injection-type new drug that blocks inflammatory pathways and inhibits cartilage cell death. Preclinical results showed that the pain relief effect lasted for several months with just one administration, and it also improved effects on cartilage damage, the root cause of arthritis. It has showed the possibility of developing a new drug that is different from existing pain relief symptomatic drugs. Currently, the drug is in Phase I/II stage of its development for the treatment of Knee Osteoarthritis.

 

Get a detailed analysis of the latest innovations in the Knee Osteoarthritis pipeline. Explore DelveInsight’s expert-driven report today! @ Knee Osteoarthritis Unmet Needs

 

Knee Osteoarthritis Companies

Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Centrexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, AbbVie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Eupraxia Pharmaceuticals, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, PT. Prodia Stem Cell Indonesia and others.

 

Knee Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Knee Osteoarthritis Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Download DelveInsight’s latest report to gain strategic insights into upcoming Knee Osteoarthritis Therapies and key Knee Osteoarthritis Developments @ Knee Osteoarthritis Market Drivers and Barriers, and Future Perspectives

 

Scope of the Knee Osteoarthritis Pipeline Report

• Coverage- Global
• Knee Osteoarthritis Companies- Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Centrexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, AbbVie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Eupraxia Pharmaceuticals, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, PT. Prodia Stem Cell Indonesia and others.
• Knee Osteoarthritis Therapies- Civamide, Clodronate, LBSA0103, Glucosamine and chondroitin sulfate combination (Eurofarma), RN624 (PF-04383119) and others.
• Knee Osteoarthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Knee Osteoarthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Which companies are leading the race in Knee Osteoarthritis drug development? Find out in DelveInsight’s exclusive Knee Osteoarthritis Pipeline Report—access it now! @ Knee Osteoarthritis Emerging Drugs and Major Companies

 

Table of Content

1. Introduction
2. Executive Summary
3. Knee Osteoarthritis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Knee Osteoarthritis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Lorecivivint: Biosplice Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. EP-104IAR: Eupraxia Pharmaceuticals Inc
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. LG00034053: LG Chem
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Knee Osteoarthritis Key Companies
21. Knee Osteoarthritis Key Products
22. Knee Osteoarthritis Unmet Needs
23. Knee Osteoarthritis Market Drivers and Barriers
24. Knee Osteoarthritis Future Perspectives and Conclusion
25. Knee Osteoarthritis Analyst Views
26. Knee Osteoarthritis Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/tay-sachs-disease-market